#Bayer AG (BAYN)

Prohost Letter #456 Treatments for Untreatable Diseases The revolution in biotechnology is not meant to offer just improvements on approved and marketed drugs. We are witnessing novel investigational...

Bayer Decision to Advance IONIS-FXI-LRx for Clotting Disorders On October 9, 2019 Ionis Pharmaceuticals ( IONS ) announced it had been notified by its partner Bayer ( BAYN ) about the decision to adva...

RegenxBio Rebounding RegenxBio ( RGNX ) has the viral vectors which could safely deliver genes into the cells. The firm has improved the adeno-associated viruses making them safe and effective gene de...

Compugen Again On Sept 10, 2018, we posted in The Week in Review #28 news we found very interesting about Compugen (CGEN). The news announced that Compugen has dosed its first patient in Phase 1 clini...

Finally, we are hearing what we were constantly expecting to hear coming out of Compugen’s (CGEN) technological capability. Yesterday, the U.S. Food and Drug Administration (FDA) has cleared Bayer AG’...

When we reiterated that  Illumina (ILMN)  is the engine of the biotechnology evolution we meant it. We have to add, though, that the evolution made possible by Illumina’s sequencers and next-generatio...

CRISPR Therapeutics   (CRSP) and Massachusetts General Hospital Cancer Center (MGHCC) have entered into a two-year research collaboration and license option agreement to develop Novel T cell therapies...